earticle

영어

Drug resistance of cancer cells has emerged as one of the cardinal issues in cancer therapy for effective customizable treatment for cancer patients. Epidermal growth factor receptor (EGFR) mutations are potential markers and determinants for predicting responses of cancer patients to tyrosine kinase inhibitors (TKIs, e.g.; gefitinib and erlotinib) therapy. Here, we have evaluated the clinical applicability of detecting lung cancer cells using molecular beacon probes targeting
mutant EGFR with the real-time PCR based assay and in situ fluorescence image approach. These methods provide a faster and easy method to monitoring for clinically relevant mutations and response to EGFR-specific tyrosine kinase inhibitor treatment in lung cancer